NAGE (Niagen Bioscience) Future 3-5Y EPS without NRI Growth Rate : 40.91 (As of Mar. 28, 2025)

View and export this data going back to 2008. Start your Free Trial

What is Niagen Bioscience Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Niagen Bioscience's Future 3-5Y EPS without NRI Growth Rate is 40.91.

Competitive Comparison of Niagen Bioscience's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Niagen Bioscience's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Niagen Bioscience's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Niagen Bioscience's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Niagen Bioscience (NAS:NAGE) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Niagen Bioscience Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Niagen Bioscience's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Niagen Bioscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Niagen Bioscience Inc (NAS:NAGE) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

OCD1:Germany

Address

10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024

Website

https://www.niagenbioscience.com

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.

Executives

Jaksch Frank L Jr	director, 10 percent owner, officer: Chief Executive Officer	10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Kristin Patrick	director	3329 CAY DRIVE, SHERMAN OAKS CA 91423
Brianna Gerber	officer: SVP Finance / Interim CFO	C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd	10 percent owner	C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Robert N Fried	director	100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing	10 percent owner	79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly	10 percent owner	SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi	director	C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen	director	C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Ng Wang Yu Gary	director	ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy	director	2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington	officer: General Counsel	53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr	officer: Chief Financial Officer	MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245